In addition to its role in invasion and metastasis of several tumors, the multifunctional urokinase receptor uPAR (urokinase plasminogen activator receptor) is directly involved in the growth of several cancer cells in vitro and in vivo. We have compared growth rate and oncogenic transformation in wild-type (wt) or uPAR À/À mouse embryonic fibroblasts (MEFs). Surprisingly, uPAR
Introduction
The GPI-anchored urokinase receptor uPAR (urokinase plasminogen activator receptor) is formed by three cysteine-rich CD59-like extracellular domains connected by short linker regions (Ploug, 2003) . The amino terminus of the receptor, domain D1, is the primary site for binding urokinase (uPA), but binding occurs in a pocket formed by all three domains (Llinas et al., 2005; Huai et al., 2006) . UPA converts plasminogen to the serine protease plasmin, which degrades fibrin and activates other zymogens like pro-matrix metalloproteinases (Blasi and Carmeliet, 2002) .
Both uPA and uPAR are overexpressed in most tumor cell lines. In human tumors, their high level is directly related to the decreased chances of disease-free survival (Reuning et al., 1998; Stephens et al., 1999; Dano et al., 2005) . In some cancers, uPA and uPAR are expressed by cancer cells, whereas in others, they are expressed by stromal cells . The proteolytic activity of cancer cells depends on both paracrine and autocrine mechanisms. An autocrine mechanism responsible for complete occupancy of the cellular uPAR confers a higher level of cell surface plasminogen activation activity (Stoppelli et al., 1986; Stephens et al., 1989) .
UPA-uPAR interaction induces, in addition to proteolysis, also intracellular signaling, affecting migration and proliferation in a variety of cells. These effects are mediated by interactions with the extracellular domains of transmembrane proteins including integrins, low density lipoprotein receptor-related protein, epidermal growth factor (EGF) receptor, platelet derived growth factor (PDGF) receptor and the G-proteincoupled receptors FPRL1 (FMLP-Receptor-Like Protein 1) and FPR (FMLP-Receptor) (Blasi and Carmeliet, 2002; Kiyan et al., 2005; Selleri et al., 2005) . Several evidences underline a direct participation of uPAR in controlling cell proliferation (Mazzieri and Blasi, 2005) . First, an uPAR-dependent pathway that controls cancer cell proliferation in vitro and in vivo has been characterized. UPAR and a5b1 induce EGFindependent but focal adhesion kinase-dependent EGF-R activation, generating high extracellular signalregulated protein kinase (ERK) and low p38 activity, conditions necessary for the growth of cancer cells in vivo (Aguirre-Ghiso et al., 1999 , 2003 Liu et al., 2002) . Second, uPA and uPAR antagonists prevent not only invasiveness and metastasis dissemination but also tumor growth (Crowley et al., 1993; Min et al., 1996; Lakka et al., 2001; Ploug et al., 2001) . Finally, a genetic screen in Ink4a À/À mice identified uPAR as a potential cooperating oncogene (Lund et al., 2002) . As the Ink4a locus controls both p53 and Rb pathways through the p19 and p16 gene products (Sharpless and DePinho, 1999) , these data suggest that uPAR overexpression may participate in tumorigenesis in the absence of cell cycle control.
We have therefore tested whether uPAR plays a role in cell proliferation using primary murine embryonic fibroblasts (MEFs) (thus lacking uncharacterized oncogenic mutations) isolated from uPAR þ / þ and uPAR
mice. The results show a direct link between uPAR expression, cell growth control and oncogenic transformation.
Results
Altered growth properties of uPAR À/À MEFs Fibroblasts (MEFs) from uPAR þ / þ , uPAR þ /À and uPAR À/À littermate mouse embryos were isolated and compared for their in vitro growth properties. To reduce the individual variability, MEFs isolated from embryos of the same litter and having the same genotype were pooled together and independent pools were analysed in different experiments.
Early-passage (P2) MEFs were grown in the presence of 10% fetal calf serum (FCS) and their growth rate was measured over a 15-day period. Surprisingly, uPAR À/À MEFs grew significantly faster than wild-type (wt) or uPAR þ /À MEFs ( Figure 1a) . In five experiments performed using independent MEF preparation, the difference in cell number was statistically significant (day 9, Po0.0262; day 12, Po0.0446). The same result was obtained with later passage MEFs (data not shown).
We compared apoptosis and cell cycle rate in early (P2) and later (P5) passages in wt and uPAR À/À MEFs. Cytofluorimetric measurements showed that uPAR À/À MEFs displayed a lower proportion of cells in the G1 and S-phases and a pronounced increase in the proportion of cells in the G2/M-phase (Figure 1b) . Propidium iodine staining and Annexin V binding were identical, indicating no difference in the apoptotic rate between wt and uPAR À/À MEFs (data not shown). We next tested that the increased growth rate of the uPAR À/À MEFs was indeed due to the lack of uPAR, by infecting wt and uPAR À/À MEFs with retroviruses expressing murine or human uPAR. As shown in Figure 1c and d, overexpression of uPAR decreased the growth rate of uPAR À/À and wt MEFs. Moreover, as in human tumors and in cell lines uPAR is often found in a truncated form cleaved between domains 1 and 2 (Hyer-Hansen et al., 1992), we have also tested whether cleavage affects the growth-inhibiting activity of uPAR. Hence we have infected uPAR À/À MEFs with retroviruses expressing wt or D2D3 human uPAR. Both forms, including or not the chemotactic epitope of uPAR (D2D3 þ and D2D3À; Fazioli et al., 1997) , were used. As shown in Figure 1d , not only full-length, but also both truncated forms of uPAR inhibited cell proliferation. Overall, these data confirm that uPAR has a direct role in controlling cell proliferation in MEFs, and exclude a role of the hD2D3 þ binding FPRL1 receptor in mediating growth inhibition.
Finally, as uPAR overexpression may participate in tumorigenesis in the absence of the Ink4a gene products (Lund et al., 2002) we analysed p19 À/À MEFs, lacking one gene product of this locus, and found that uPAR overexpression failed to decrease growth (Figure 1e ), even though it did not stimulate it like Ras V12 . Thus, uPAR can affect cell proliferation only in a p19-positive background.
To characterize the basis for the higher proliferation rate of uPAR À/À MEFs, we measured the ratio of ERK-to-p38 MAP kinases in early (P4) passage wt and uPAR À/À MEFs. The levels of phosphorylated ERK and p38 were compared to total ERK or p38 levels. uPAR
MEFs showed higher levels of ERK activation than wt MEFs and a higher ERK-to-p38 ratio, consistent with their higher proliferation rate (Figure 2a and b) .
The dimeric trascription factor activator protein-1 (AP-1) is an important multifunctional downstream effector of both ERK and p38 MAP kinase (Karin et al., 1997) and so we analysed the levels of the AP-1 complex family members in wt and uPAR À/À MEFs. At passage 4, the levels of Fra1, JunB, JunD and cJun were higher in uPAR À/À MEFs ( Figure 2c ). We next focused our attention on the level of the cell cycle modulator cyclin D1, a direct target gene of AP-1 complexes (Shaulian and Karin, 2001) , also treating cells with the proteasome inhibitor MG132 for the indicated times. Cyclin D1 levels were measured by Western blot analysis and normalized to actin expression (Figure 2d and e). UPAR À/À MEFs showed a higher level of cyclin D1 both in the absence and in the presence of MG132. Overall, the data show a correlation between the growth advantage of uPAR À/À MEFs and a higher level or activation of several growth-promoting proteins.
The transforming activity of Ras V12 -E1A is higher in uPAR À/À MEFs Passage 4 wt, uPAR þ /À and uPAR À/À MEFs were coinfected with retroviral vectors encoding H-Ras V12 and E1A. Infected cells were grown to confluence, pooled and analysed. The data below refer to two experiments with different pools of MEFs.
We tested the presence, and level, of the two oncogenic proteins by Western blot analysis on total cell extracts and by immunofluorescent co-staining of fixed cells. The level of E1A and Ras V12 in the three cell types was comparable and over 90% of the cells expressed both oncogenes (data not shown).
We compared the transformation efficiency in the three genotypes. The in vitro growth rate of the transformed cells was analysed measuring the number of cells after 3 days of culture in 10% serum. As shown in Figure 3a , Ras V12 -E1A-transformed uPAR À/À MEFs (ko-RE) produced more cells than transformed heterozygous (het-RE) and wt MEFs (wt-RE). The growth differences were not due to differential apoptosis ( Figure 3c ). Other typical transformation parameters, that is, growth in low serum, anchorage independence (colony formation in soft agar) and formation of solid tumors in nude mice, also followed the same trend.
uPAR regulates cell growth in primary embryo fibroblasts
In vitro, ko-RE cells grew faster than wt-RE in low serum ( Figure 3b ) and formed more colonies when plated in soft agar ( Figure 4a ). In vivo, ko-RE cells formed tumors much earlier than het-RE and wt-RE, and hence reached a significantly larger size 3 weeks after injection (Figure 4b ). In Figure 4c , each line represents the growth of an individual tumor showing that wt-RE cells were able to produce tumors, but later than ko-RE cells. Table 1 summarizes the results obtained in three different experiments in which a total of 15-20 mice were inoculated with transformed cells of each genotype. The uPAR genotype did not affect the ability to form tumors (Table 1) ; however, 22 days after inoculation, ko-RE tumors were much larger than wt-RE tumors and this difference was statistically significant (Table 1) . Het-RE MEFs displayed an intermediate phenotype with respect to all these properties.
We conclude that the transforming activity of Ras V12 -E1A is increased in uPAR À/À cells in comparison to wt. Interestingly, the growth properties of parental and transformed cells are dependent on uPAR concentration, as the heterozygous uPAR þ /À cells had always an intermediate behavior. À and hD2D3 þ indicate constructs including ( þ ) or not the chemotactic epitope of uPAR (Fazioli et al., 1997) . Cells were plated at low density and growth was measured over a 12-day period. The mean7s.d. of triplicate samples are reported. (e) Growth rate of p19ARF À/À MEFs infected with uPAR, Ras V12 and GFP as control. Cells were plated at low density and growth was measured over a 14-day period. The mean7s.d. of duplicate samples are reported.
uPAR regulates cell growth in primary embryo fibroblasts R Mazzieri et al 2005). In various cancer models, the inhibition of uPAR expression, or activity, decreases tumor growth (Kook et al., 1994; Wilhelm et al., 1994; Min et al., 1996; Ossowski and Aguirre-Ghiso, 2000; Lakka et al., 2001; Ploug et al., 2001; Mazzieri and Blasi, 2005) . Most of the studies on uPAR and cancer, while definitely connecting uPAR with cancer, were performed either on tumor cell lines or in patients after cancer diagnosis, that is, under conditions where many (mostly uncharacterized) mutations had already accumulated. We have studied cell proliferation in primary mouse embryonic fibroblasts, a model extensively employed to study proliferation under both normal and transformed conditions (Hahn and Weinberg, 2002) .
We have found that uPAR À/À MEFs have a higher proliferation rate than wt MEFs (Figure 1a) , independent of the passage in culture (not shown). The results obtained are statistically significant and do not depend on difference in genetic background.
UPAR À/À MEFs show higher levels of basal P-ERK, Fos and Jun-family members of the AP-1 complex as well as of cyclin D1 (Figure 2) . ERK is a known downstream effector of various transmembrane signal-transducing receptors involved in cell proliferation (Hahn and Weinberg, 2002) . AP-1 activity is induced by several extracellular signals including growth factors, cytokines and cell-matrix interactions (Shaulian and Karin, 2002) . Likewise, AP-1 proteins bind to and activate the cyclin D1 promoter (Shaulian and Karin, 2002) , thereby providing a direct link between the increase in AP-1 activity and the accelerated cell cycle. Thus, the biochemical findings explain the higher proliferation rate of uPAR À/À MEFs. We conclude that in MEFs, uPAR exerts a negative physiological control on cell proliferation. Indeed, overexpression of uPAR reverts the phenotype and decreases the growth rate of uPAR À/À as well as wt MEFs (Figure 1) . Interestingly, both human and mouse uPAR (despite their not insignificant sequence-differences) induced growth inhibition in both wt and uPAR
MEFs. This indicates that the binding of endogenous uPA to uPAR is not involved in the growth-inhibiting effect, as mouse uPA does not bind human uPAR (Estreicher et al., 1989) . Also the finding that the cleaved D2D3 form of uPAR induces growth inhibition agrees with the above interpretation, as the D2D3 form essentially does not bind uPA (Behrendt et al., 1991) .
If uPAR negatively controls growth rate in MEFs, we would expect uPAR À/À cells to be more easily transformed and produce faster-growing tumors. Indeed, the growth advantage of uPAR À/À over wt and heterozygous MEFs was maintained in vitro and in vivo (Figures 3  and 4 , and The levels of active (P-ERK1/2) and total ERK (tot-ERK2) and the levels of active (P-p38) and total p38 (tot-p38) were determined by Western blot analysis on total cell extracts from P4 uPAR þ / þ and uPAR À/À MEFs. (b) Densitometric analysis of Western blots described in (a); the phospho-enzyme to total enzyme ratio is expressed as fold increase over that of wild type cells, which was arbitrarily set as 1. The mean7standard error of the mean (s.e.m.) of one experiment (reproduced three times) performed in duplicate are reported. (c) Protein levels of Fos and Jun-family members detected by Western blot analysis on total cell extracts from P4 uPAR þ / þ and uPAR À/À MEFs. (d) Protein levels of Cyclin D1 detected by Western blot analysis on total cell extracts from P4 uPAR þ / þ and uPAR À/À MEFs incubated in the absence (0 h) or in the presence (1, 2 and 12 h) of the proteosome inhibitor Mg132. (e) Densitometric analysis of Western blots described in (d); the Cyclin D1 to actin ratio is expressed as fold increase over that of wild type cells at 0 h, which was arbitrarily set as 1. The mean7s.d. of three independent experiments are reported. uPAR regulates cell growth in primary embryo fibroblasts R Mazzieri et al than their wt counterpart, producing bigger tumors. Interestingly, heterozygous MEFs displayed an intermediate behavior. Thus, our results show a concentration-dependent control of cell growth by uPAR, in both wt and transformed MEFs. The conclusion that uPAR affects negatively cell growth goes against the large amount of evidence showing that uPAR is overexpressed in human tumors and that uPAR overexpression stimulates cell growth. One can explain this discrepancy in at least two ways. First, unlike primary MEFs, human tumors and tumor cell lines harbor mutations activating oncogenes and inactivating tumor suppressor genes. Thus, the effect of uPAR on cell proliferation may change depending on which proto-oncogenes and/or tumor suppressor genes are mutated in the cell. Indeed, uPAR is detected as a potential cooperating oncogene in Ink4a Ko mice (Lund et al., 2002) . Ink4a Ko mice do not express p16 or p19ARF and are deficient in cell growth control (Serrano et al., 1996) . Indeed, we show that uPAR overexpression did not decrease the growth rate in p19ARF À/À MEFs (Figure 1e ). The second possible explanation is that the effect of uPAR on growth rate may depend on cell type. Although we have obtained similar results with osteoblasts (F Furlan and F Blasi, unpublished) , new-born keratinocytes appear to behave in the opposite way, that is, in these cells uPAR may be required for cell growth (D'Alessio and F Blasi, unpublished) . This differential role of uPAR may be relevant in human tumors, where uPAR is expressed by either stromal or cancer cells.
Not much is known of the nature of the link connecting uPAR with cell proliferation. The data of Figure 1d exclude the FPRL1 interaction. Available data in cultured cancer cells, however, indicate that uPAR overexpression activates cell proliferation by interacting with integrins and with growth factor receptor tyrosine kinases like the EGF and the PDGF receptors (Liu et al., 2002; Kiyan et al., 2005) . However, peptide a325 that dissociates uPAR-a3b1 and -a5b1 complexes (Wei et al., 2001; Mazzieri et al., 2006) had no effect on wt MEFs growth rate or ERK activation (data not shown). It is known that overexpression of uPAR in Hep3 cells, for example, modifies the response of the EGF-R to EGF, so that EGF-R was activated in the absence of EGF (Liu et al., 2002) . In human cancer cells, overexpression of uPAR does not appear to be correlated to overexpression of EGF-R (Marco Pierotti, personal communication). On the other hand, direct experimental demonstration of uPAR/EGF-R functional interaction in vivo is still outstanding. In cell culture, on the other hand, different uPAR conformations are able to differentiate between different interacting proteins, that is, EGF-R or integrins (Mazzieri et al., 2006) . A detailed mutation study of uPAR will uPAR regulates cell growth in primary embryo fibroblasts R Mazzieri et al probably allow to describe accurately the molecular mechanism (and interactors) involved in its role in growth control.
Materials and methods

MEFs derivation and culture conditions Homozygous uPAR
þ / þ and uPAR À/À mice (75% C57B/6 Â 25% 129/Sv background) were provided by Dr Peter Carmeliet (Leuven, Belgium) (Dewerchin et al., 1996) . E13.5 MEFs were isolated from uPAR þ / þ , uPAR þ /À and uPAR À/À littermate embryos as described (Todaro and Green, 1963) . Genotyping was performed by PCR analysis using the following sets of primers: (1) Wt-forward: 5 0 -cacacctggaactctattactagg-3 0 Wt-reverse: 5 0 -acgcccgactcaccgggtctgggcctgttgcag-3 0 ; (2) Ko-forward: 5 0 -cgac agggaacgaagatgagcac-3 0 ; Ko-reverse: 5 0 -cgcagcgcatcgccttctatcg cc-3 0 . Annealing temperature of 601C and 35 cycles were used to amplify the wt (550 bp) and Ko (800 bp) products. After genotyping, MEFs with the same genotype were pooled with the same litters. p19ARF À/À MEFs were provided by Dr Cristina Moroni (IEO, Milan, Italy). Ecotropic Phoenix cells were a kind gift from Dr Anna Mondino. All cultures were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, S Giuliano Milanese, Italy) supplemented with 10% FCS (Sigma, St Louis, MO, USA), L-glutamine (100 U/ml) and penicillin/streptomycin (100 U/ml). -E1A-transformed MEFs of the indicated uPAR genotypes (wt-RE, het-RE and ko-RE) were injected into the right flank of 10 athymic nude mice and allowed to grow over a 22-day period. Tumor size was measured three times a week and plotted as tumor volume over time. MEFs; MEFs, mouse embryonic fibroblasts; het-RE, transformed heterozygous; wt-RE, wild type MEFs. One million transformed cells were injected in the right flank of athymic female mice. The tumor uptake and the tumor volume were assessed 22 days after injection (for details see Material and methods section).
Retroviral vectors and viral infection
uPAR regulates cell growth in primary embryo fibroblasts R Mazzieri et al supplemented with 5 mg/ml polybrene and used to infect MEFs. MEFs (5 Â 10 5 ) were plated 48 h before infection and selected for 4 days in puromycin (2 mg/ml) after four rounds of infection (4 h each) over a 2-day period.
Growth curves
Five thousand MEFs or 3000 RE-MEFs were seeded in 24-well plates. Fresh medium was added every 3 days. At the indicated times, cells were washed with phosphate-buffered saline (PBS), fixed in 500 ml of PBS containing 11% gluteraldehyde for 10 min at room temperature, rinsed with water and air-dried. Cells were then stained with 300 ml of 0.1% crystal violet (Sigma) in 200 mM MES, pH 6.0 (Sigma), rinsed extensively, air-dried, extracted with 500 ml of 10% acetic acid for 20 min at room temperature and the absorbance was measured at 650 nm. Each experiment was carried out in triplicate and each growth curve was performed at least three times using MEFs obtained from independent litters. Values are expressed as fold increase over day 0.
Immunoblotting analysis
Washed subconfluent MEF cultures were lysed in NP-40 lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mM sodium vanadate, 1 mM ethylenediaminetetraacetic acid). Cell lysates were cleared by centrifugation at 14 000 r.p.m. for 10 min at 41C. Electrophoresed extracts were transferred to Immobilon-P membranes (Millipore Corporation, Windsor, MA, USA), blocked in TBS-T (Tris-buffered saline, 0.05% Tween 20) containing 5% milk, incubated with appropriate primary and secondary antibodies and developed using ECL (Amersham Biosciences, Milan, Italy). The following primary antibodies were used: SC1647, SC535 and SC7973 (Santa Cruz, CA, USA) for ERK-2, p38 and phospho-p38, respectively. Anti-P-ERK1/2 antibody was from Cell Signaling Technology (Danvers, MA, USA) (cat. N9101). SC717, SC-45, SC-74, SC-605 and SC46 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used to detect cyclin D1, c-jun, junD, fra-1 and JunB, respectively. The anti H-ras V12 was a kind gift from Berthe Willumsen. Anti-murine uPAR was kindly provided by Dr S Rosenberg. Anti-actin antibody was from Santa Cruz, CA, USA. Horseradish peroxidaseconjugated anti-mouse and anti-rabbit antibodies (Amersham) were used as secondary antibodies.
Apoptosis assay
Annexin V and propidium iodide staining was performed according to the manufacturer's instructions (Apoptosis detection kit II, Molecular Probes, Eugene, OR, USA). Briefly, MEFs were washed twice in PBS and resuspended in binding buffer (10 mM HEPES/NaOH, pH 7.4 þ 140 mM NaCl þ 2.5 mM CaCl 2 ). 5 ml Annexin V-FITC and 10 ml propidium iodide were added to 100 ml of cells suspension. After 15 min, apoptotic profiles were determined by fluorescence activated cell sorting (FACS) analysis and analysed by CellQuest software.
Cell cycle analysis
For cell cycle analysis, the 5-bromodeoxyuridine (BrdU) Flow Kit (BD Bioscience, Erembodegem, Belgium) was used according to the manufacturer's instructions. Briefly, MEFs plated in P-100 dishes were serum starved for 24 h, allowed to re-enter the cell cycle in the presence of 10% FCS and 10 mM BrdU over a 4 h interval, harvested by trypsinization, fixed (BD Cytofix/Cytoperm buffer), treated with 300 mg/ml DNase for 1 h at 371C, washed (BD Perm/Wash buffer) and incubated with anti-BrdU-FITC antibody (BD Bioscience) for 20 min at room temperature. Total DNA was stained with 7-aminoactinomycin D (7-AAD) (BD Bioscience). Cell cycle profiles were determined by FACS analysis and analysed by CellQuest software.
Tumorigenicity in nude mice
Exponentially growing cells (10 7 ) were resuspended in 1 ml of PBS and 100 ml was injected subcutaneously into the flank of 5-week-old athymic nude mice (Charles River, Calco, LC, Italy). Mice were housed in a specific pathogen-free animal facility, and treated in accordance with the EU guidelines with the approval of the Institutional Ethical Committee. Tumor growth was monitored three times a week and mice were killed 22 days after injection. Tumor volume (v) was estimated using the formula v ¼ (X 2 Y)/2, where X is the length and Y is width of each tumor.
Colony-formation assay in soft agar 4 Â 10 4 cells were resuspended in 3 ml of DMEM containing 0.3% soft agar in 10% FCS and plated into a 60 mm dish above a bottom layer of DMEM, 0.6% soft agar and 10% FCS. Viable colonies, allowed to form over a 2-week period, were stained overnight with 0.5 mg/ml of (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT, Sigma)). Each cell type was plated in triplicate and the number of colonies counted in each well.
